Loading
Latest filing published 21 May 2021 for Evofem Biosciences, Inc., €30k.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Kelly Culwell, listed as senior executive, appears in our data through filings on Evofem Biosciences, Inc. shares, published by SEC (Form 4). Between 2 July 2018 and 20 May 2021, the trades on record add up to 20 filings.
Market trades split into 1 purchase (€5,910) and 4 sales (€22k). The net balance comes to €16k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 15 share grants.
On 21 May 2021 came the latest disclosure, a share grant for €30k in Evofem Biosciences, Inc. The last insider purchase was made public on 20 August 2018, 2,987 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 20 declarations